Trials / Unknown
UnknownNCT01566019
Molecular Screening for Cancer Treatment Optimization
Molecular Screening Analysis Used as Decision Tool for Targeted Molecular Treatment
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 2,150 (estimated)
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
- Sex
- All
- Age
- 6 Months
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to use high throughput molecular analysis (CGH Array and sequencing) to treat patients with metastatic cancer with targeted therapeutics in order to improve the progression free survival compared to the previous treatment line. The secondary objectives are to investigate clinical practical feasibility of such technics, to potentially improve the overall survival of patients and to describe molecular portrait of Phase 1 candidates.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Tumoral biopsy | Every enrolled patient undergoes tumoral biopsy |
Timeline
- Start date
- 2011-10-28
- Primary completion
- 2020-10-01
- Completion
- 2020-10-01
- First posted
- 2012-03-29
- Last updated
- 2020-02-17
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01566019. Inclusion in this directory is not an endorsement.